PROGRAM - 5th International Keloid Symposium - Shanghai, China
Time
Speaker
Title
DAY 1
Friday June 6, 2025
Opening of the 5th International Keloid Symposium
Co-Chair: Michael H Tirgan, MD
Panel Discussion and Q/A
10:00-10:30
Coffee Break
Co-Chair: Frank Nissen, MD, PhD
Panel Discussion and Q/A
12:20-13:30
Lunch Break
Co-Chair: Cecilia Li, MD
15:00 – 15:30
Coffee Break
15:30 – 17:30
Co-Chair: Lamont Jones, MD, MBA
Time
Speaker
Title
DAY 2
Saturday June 7, 2025
Co-Chair: Nanze Yu, MD, PhD
Yixin Zhang, MD
Molecular and Immune-Mechanism of Keloid Development.
Mark Fear, PhD
Understanding the Mechanisms of Keloid Recurrence and Exploring Novel Therapeutic Options.
Zhilian Qin, MD
Inhibition ENO1 Expression Targets the Glycolytic and Lactylation to Regulate Keloid Fibroblast Function.
Chenyu Huang, MD
Asporin Inhibits Collagen Matrix-Mediated Intercellular Mechano-Communications Between Fibroblasts during Keloid Progression.
Nanze Yu, MD, PhD
Understanding and Clinical Practice of Vascular Abnormalities in Keloid Disease.
Panel Discussion and Q/A
10:30-10:45
Coffee Break
Co-Chair: Jonathan Tsao, MD
Jonathan Tsao, MD
Adjuvant Radiotherapy for the Treatment of Keloids.
Henry Weatherburn, PhD
A Data-Based Approach to a Keloid Post-Excisional Radiotherapy Treatment (PERT) Pathway.
John Glees, MD, FRCR, DMRT
Case Studies of Patient Outcomes of Re-Treatment of Recurrent Keloid Tumours by Fractionated Superficial X-Ray Radiotherapy
Zhongling Qiu, MD
Isotope Therapy to Prevent Post-Surgical Keloid Recurrence.
Fuquan Zhang, MD
Clinical Outcomes of Electronic Beam Irradiation for Post-Surgical Keloids in a Large-scale Investigation.
Panel Discussion and Q/A
12:30-13:30
Lunch Break
Co-Chair: Henry Weatherburn, PhD
Jinglong Cai, PhD
TBD
Henry Weatherburn, PhD
A 15 Year Single Centre Audit of the Outcome of Fractionated Superficial X-Ray Radiotherapy Treatment of Recurrent Keloid Tumours.
Wei Liu, MD, PhD
Building up Multi-Level Defense Strategy for Post-Surgical Keloid Recurrence.
Xiaomei Han, MD
Full-Process Management of Auricular Keloids: The Role of the Innovative ABC Surgical Technique in a Multidisciplinary Treatment Framework.
Xiaodong Chen, MD, PhD
Nucleoresection Combined with Punch Extraction and Radiation Therapy: a Keloid Surgical Technique Worth Promoting.
15:00 – 15:30
Coffee Break
15:30 – 17:00
Co-Chair: Michael Tirgan, MD
Qiqi Yin, MD
Current Practices in Keloid Treatment. A Survey of Dutch Dermatologists and Plastic Surgeons.
Qian-Yu Ma, MD, PhD
Laser combined with radiotherapy for keloid treatment: a novel and efficient comprehensive therapy with a lower recurrence rate.
Binrong Zhou, MD
Novel Needle-Type Electrocoagulation and Combination Pharmacotherapy: Basic and Clinical Studies on Efficacy and Safety in Treating Keloids.
Xiaoli Wu, MD, PhD
LCR Technique for Keloid Treatment
Wenbo Wang, MD, PhD
An Innovative Single-Stage Approach of High-Tension Keloid Excision and Reconstruction Using Acellular Dermal Matrix and Epidermal Skin Grafting.
16:30-17:00
Lamont Jones, MD, MBA<br>
The Annual Jouni Uitto, MD, PhD International Visiting Professorship and Lecture in Molecular Dermatology<br>
Clinical Biomarkers: The Future of Keloid Disease’s Diagnosis and Treatment.
Time
Speaker
Title
DAY 3
Sunday June 8, 2025
Co-Chair: Wei Liu, MD, PhD
Michael H. Tirgan, MD
Pediatric Keloids: Case Review, Clinical Patterns, and Treatment Recommendations.
Xiqiao Wang, MD
Microbiome Dysbiosis Dominated by Rhodococcus Occurs in Keloids
Juliette Louter
How do I Deal with the Keloid Disease: a Qualitative Study Exploring Coping Strategies in a Multicultural Adult Patient Population.
Zhongyao Liang, MD, PhD
Linagliptin, a Potentially more Effective Drug for the Treatment of Keloids than 5-FU.
Zhehu Jin, MD, PhD
Real‑World Effectiveness and Safety of Bleomycin in Patients with Keloids and Hypertrophic Scars: a Systematic Review and Meta‑Analysis
Quqi Yin, MD
The Biodistribution of Triamcinolone Acetonide Injections in Severe Keloids, an Exploratory Three-Dimensional Fluorescent Cryomicrotome Study.
Yuting Huang, RN
Coping Tendencies Play a Partial Mediating Role between Social Support and Anxiety/Depression among Chinese Keloid Patients.
Panel Discussion and Q/A
10:30-10:45
Coffee Break
Co-Chair:
Cecilla Li, MD
Novel Concept and Clinical Practice of Keloid Pressure Therapy
Chunhui Xie, MD
Application of Core Excision in the Treatment of Keloids.
Yan Hao, MD
Clinical Observation of Subepidermal Vascular Network Flaps in Keloid Patients.
Bing Li, MD, PhD
Surgery Approaches and Experiences for Keloid Treatment and the Adjunctive Therapy.
Panel Discussion and Q/A
12:30-13:30
Lunch Break
Co-Chair: Lamont Jones, MD, PhD
Akash Gunjan, PhD
Rationale Based Repurposing of FDA-Approved Agents for Keloid Management: An in Vitro Study.
Lian Zhang, MD
Integrated Multi-Omics Unveils the Epigenetic Landscape in the Pathogenesis of Keloid.
Chengcheng Deng, PhD
BMP2-Induced Adam12+ Fibroblasts Dictate Skin Scarring and Fibrosis.
Tianhao Li, PhD
TWIST1 Promote TGF-β Receptor I in Keloid Fibroblasts via Regulating the Stability of MEF2A.
Tianhao Li, PhD
Integrated Analysis of TWIST1 in Keloid Pathogenesis: Single-Cell Transcriptomics Reveals Fibroblast Heterogeneity and a Novel MEF2A-TBR1 Regulatory Axis.
Mengjie Shan, MD, PhD
Multi-Omics Analyses Reveal Bacteria and Catalase Associated with Keloid Disease.
Yixin Sun, MD, PhD
Single-Cell RNA Sequencing Revealed Key Factors of EMT to Promote Fibroblast Activation and Immune Infiltration in Keloid
Junxian Wen, PhD Candidate
Endothelial Dysfunction in Keloid Formation and Therapeutic Insights.
Lian Zhang, MD, PhD
Integrated Multi-Omics Unveils the Epigenetic Landscape in the Pathogenesis of Keloid.
15:15 – 15:30
Coffee Break
15:30 – 17:00
Co-Chair:
Shuchen Gu, MD, PhD
Targeting the Nuclear Long Noncoding Transcript LSP1P5 Abrogates Extracellular Matrix Deposition by Trans-Upregulating CEBPA in Keloids.
Xinwen Kuang, MD, PhD candidate
Multi-Dimensional Effects of Hydrogen-Rich Materials on Wound Healing and Alleviating Skin Fibrosis.
Shuo Li, MD, PhD
Establishment of a Deep Learning-Based Automated Segmentation and Blood Perfusion Prediction System for Keloids.
Zhijin Li, PhD
Unraveling the Vascular Tapestry: Endothelial Dysfunction in Keloid Formation and Therapeutic Insights.
Ruoqing Xu, MBBS, PhD
ALKBH5-Mediated m6A Demethylation Ameliorates Extracellular Matrix Deposition in Cutaneous Pathological Fibrosis.
Ruoqing Xu, MBBS, PhD
ALKBH5-Mediated m6A Demethylation Ameliorates Extracellular Matrix Deposition in Cutaneous Pathological Fibrosis.
En Yang, MD, PhD
Single Cell Deciphering of Pruritic Keloids: the Interaction Between Fibroblasts and Schwann Cells Through the Midkine Signaling.
Yingrou Tan, PhD
Dual siRNAs Nanoplex Targeting IL-4RA and SPARC Enhance Collagen Reduction in IL-4 Activated Skin Fibroblasts.
Junxian Wen, MD
Insights from Comparing Blood Perfusion Metrics and Vancouver Scar Scale in Keloid Assessment.
Tu Liying, MD, PhD
ALKBH3-Mediated m1A Demethylation of METTL3 Endows Pathological Fibrosis: Interplay Between m1A and m6A RNA Methylation.
13:30 – 15:00
Co-Chair: Frank Nissen, MD, PhD
Michael H Tirgan, MD
Cartesian Model of Clinical Behavior of Keloid Disorder.
15:30 – 16:30
Co-Chair: Frank Nissen, MD, PhD
Michael H Tirgan, MD
Contact Cryotherapy in Treatment of Keloid Lesions, Indications and Case Studies.
